As European markets grapple with concerns over U.S. Federal Reserve independence, renewed tariff uncertainties, and political instability, the pan-European STOXX Europe 600 Index recently ended 1.99% lower. In this environment of heightened volatility and economic uncertainty, growth companies with high insider ownership can be appealing as they often indicate strong internal confidence in the business’s future prospects and alignment with shareholder interests.
Name
Insider Ownership
Earnings Growth
Pharma Mar (BME:PHM)
11.8%
44.2%
MilDef Group (OM:MILDEF)
13.7%
73.9%
Marinomed Biotech (WBAG:MARI)
29.7%
20.2%
KebNi (OM:KEBNI B)
38.4%
63.7%
Elliptic Laboratories (OB:ELABS)
24.4%
97.5%
CTT Systems (OM:CTT)
17.5%
37.9%
Circus (XTRA:CA1)
24.5%
72.6%
CD Projekt (WSE:CDR)
29.7%
42.7%
Bonesupport Holding (OM:BONEX)
10.4%
59.7%
Bergen Carbon Solutions (OB:BCS)
12%
64.6%
Click here to see the full list of 216 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK40.99 billion.
Operations: The company’s revenue is primarily derived from its Healthcare Services segment, which generated €1.58 billion, and its Diagnostic Services segment, which contributed €703.20 million.
Insider Ownership: 11.2%
Earnings Growth Forecast: 28.7% p.a.
Medicover demonstrates strong growth potential, with earnings forecasted to grow significantly at 28.72% annually, outpacing the Swedish market. Insider ownership remains high with more shares bought than sold recently. The company is actively seeking acquisitions to enhance its strategic position despite a high current ratio. Recent financial results show robust performance, with a notable increase in net income and sales for the first half of 2025 compared to the previous year.
OM:MCOV B Ownership Breakdown as at Sep 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: Smart Eye AB (publ) specializes in developing AI technology solutions that analyze and predict human behavior across various regions, with a market cap of SEK3.11 billion.
Operations: Smart Eye AB’s revenue is primarily derived from its Behavioral Research segment, accounting for SEK249.10 million, and its Automotive Solutions segment, contributing SEK112.45 million.
Insider Ownership: 15.2%
Earnings Growth Forecast: 104.2% p.a.
Smart Eye’s revenue is forecasted to grow at 46.1% annually, significantly outpacing the Swedish market. The company recently reported a reduced net loss for Q2 2025, reflecting improved financial performance. Recent product innovations like AI ONE and an upgraded AIS system highlight its technological advancements in driver monitoring systems. Despite having less than a year’s cash runway, Smart Eye trades at 61% below estimated fair value and aims for profitability within three years, with no recent insider trading activity noted.
OM:SEYE Ownership Breakdown as at Sep 2025
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Stratec SE, with a market cap of €320.92 million, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally.
Operations: The company’s revenue segment includes €263.52 million from automation solutions for highly regulated laboratories.
Insider Ownership: 30.9%
Earnings Growth Forecast: 21.5% p.a.
Stratec SE’s earnings are projected to grow at 21.5% annually, surpassing the German market average. Although revenue growth is forecasted at 6.6% per year, it remains below 20%. The company trades at a significant discount to its estimated fair value but has debt concerns with operating cash flow coverage. Recent earnings showed a decline in net income despite increased sales, and the dividend was raised to €0.60 per share for 2024, reflecting shareholder engagement.
XTRA:SBS Earnings and Revenue Growth as at Sep 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OM:MCOV B OM:SEYE and XTRA:SBS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
